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Albuminuria as a surrogate marker for drug development: A
European Regulatory perspective. Clinical trials with surrogate
end points generally require smaller sample sizes and shorter
duration than those with clinical outcomes. However, in prac-
tice, surrogate end points are likely to result in less comprehen-
sive conclusions than ‘outcome’ end points as they sometimes
reflect only partial aspects of complex phenomena. A number of
conditions help to establish the validity of a particular variable
as predictive of clinical outcome. This article discusses to what
extent albuminuria fulfills these requisites in two particular clin-
ical scenarios: prevention of renal deterioration and prevention
of cardiovascular disease.
SURROGATE END POINTS AND DRUG
REGISTRATION
A surrogate variable can be defined as that provid-
ing an indirect measurement of effect in situations where
direct measurement of clinical benefit is not feasible
or practical [1]. Classic examples include glycosylated
hemoglobin as surrogate for diabetes morbi-mortality,
plasma viral load for AIDS-related morbi-mortality, or
blood pressure for cardiovascular morbi-mortality. Clini-
cal trials with surrogate end points as their main variable
generally require smaller sample sizes, and may be of
shorter duration than those with directly meaningful end
points. It is tempting, then, to use them for regulatory pur-
poses (i.e., for registration) in order to reduce the time
and resources needed to make new medicines officially
available for a particular target population. This would
appear theoretically acceptable provided that the pre-
dictive value of such variable is strictly validated for the
actual circumstances of each trial. However, in practice,
surrogate end points are likely to result in less compre-
hensive conclusions than ‘outcome’ end points because
they sometimes reflect only partial aspects of complex
phenomena. Their acceptability would depend not only
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on how much more feasible they are than the ‘true’ end
points (what is too cumbersome to measure in day to
day clinical practice may well be desirable within the for-
mal context of a clinical trial), but also on the need for
the potential new substance (would it be used for unmet
medical needs, justifying accelerated approval at the ex-
pense of some uncertainty? Are there alternatives with
documented effects on outcome end points?). It has to
be considered that approving drugs based only on sur-
rogates may be seen as approving them based on logic,
rather than on proof.
Not surprisingly, then, the use of surrogate end points
for regulatory purposes is a matter of controversy [2–
5]. In addition, a number of assumed surrogate variables
have eventually failed to predict real clinical benefit, par-
ticularly in the cardiovascular field [3, 4]. As Fleming and
DeMets state, “a correlate does not necessary make a
surrogate.” [2] A number of requisites help establish the
validity of a particular variable as predictive of clinical
outcome: (1) biological plausibility—the variable plays a
role in the pathophysiologic mechanism of the disease so
that a change in it would be expected to result in a change
in the disease pathway; (2) experimental and/or epidemi-
ologic evidence of a relationship between the variable
and the clinical outcome so that the assumed surrogate
can be considered as a risk factor for the disease; and
(3) good correlation, both qualitative and quantitative,
between the variable and the clinical outcome. It should
ideally be known what percentage of the treatment effect
in terms of clinical outcome is explained by the effect of
the drug on the surrogate variable. This is a difficult aspect
when validating a variable, also because the correlation
may depend on the mechanism of the studied drug so that
extrapolations between drugs with different mechanisms
may not be adequate.
ALBUMINURIA AS A SURROGATE END POINT
The validity of albuminuria as a surrogate marker of
clinical outcome can be contemplated in two scenarios: as
a marker of renal disease progression, and as a predictor
of cardiovascular morbi-mortality.
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Prevention of renal deterioration
Albuminuria has been advocated not only as a mere
marker of renal deterioration reflecting an abnormality
in glomerular permeability, but also as a contributing fac-
tor to the actual mechanism of renal damage [6, 7]. The
appearance of albumin in the urine would be a necessary
early step in some forms of renal disease. Albuminuria
would then be an intermediate [4], rather than a surro-
gate, variable, and assessing the transition from microal-
buminuria to macroalbuminuria could well be judged as
a ‘true clinical’ end point, reflecting progression of the
disease. The fact that some studies have failed to show
that favorable drug effects on the rate of progression
from micro- to macroalbuminuria translated into an im-
proved course of the glomerular filtration rate (GFR) [8],
might be explained if it is considered that microalbumin-
uria occurs at a very early stage of the disease, when the
GFR is slightly affected. The available clinical data seem
to support such idea: therapeutic interventions slowing
the progression from microalbuminuria to macroalbu-
minuria have also shown efficacy at latter stages of the
disease using harder end points (doubling serum creati-
nine and progression to ESRD) [9–11].
However, some issues deserve further consideration
before albuminuria, although plausible, can be accepted
as a self-standing end point in studies aimed at being the
main proof of efficacy for a new drug: (1) To what ex-
tent can a reliable quantitative relationship between a
drug effect on albuminuria at an early stage of the disease
and the drug effect on the final outcome of the disease
currently be established with the available information?
(2) To what extent can such a quantitative relationship
be considered consistent and homogeneous across renal
impairment of different origins (e.g., diabetic nephropa-
thy, hypertensive nephropathy) and across drugs of dif-
ferent classes/with different mechanisms of action? A
relationship between an initial effect on the rate of albu-
min excretion and a decrease in the kidney deterioration
process has been seen with several drugs acting on the
renin-angiotensin-aldosterone system in different set-
tings. How far can this be generalized? (3) To what extent
can the above-mentioned factors be integrated in order to
define a reasonably clinically meaningless noninferiority
margin when comparing different therapeutic strategies?
Cardiovascular prevention
The value of albuminuria as a surrogate end point for
cardiovascular prevention strategies is much less clear.
It has been shown to be a predictor of cardiovascular
risk [12–13]. Microalbuminuria has been already used
as a relevant criterion delineating a high cardiovascular
risk population in clinical studies [14]. However, its phys-
iopathologic implication in such a multifactorial situation
is probably too variable and, in any case, not completely
elucidated. Assessing to what extent the effect of a ther-
apeutic intervention aimed at preventing cardiovascular
morbi-mortality could be explained through its incidence
on the rate of albumin excretion may prove difficult. In
this regard, some of the available data show that, in type 2
diabetes, ARA-2 inhibitors are more effective than other
alternatives on renal parameters, but not so when com-
paring cardiovascular end points [15]. Therefore, a more
direct estimation of effect appears preferable.
CONCLUSION
Although some issues need further discussion, there
can be a case for accepting albuminuria in well-chosen
situations as a valid surrogate end point for renal function
deterioration in clinical trials, in particular, if supported
by complementary evidence. The available information
does not allow considering albuminuria as a valid surro-
gate to predict clinical outcome in therapeutic strategies
aimed at cardiovascular prevention.
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